Abstract:Coronary heart disease (CHD) is a leading cause of death in the US. CHD associated morbidity and mortality can be reduced if those at risk can be identified well in advance, to put in place prevention interventions prior to an acute coronary event. Limitations of current approaches call for additional efforts to improve risk predictions. We recently developed a Precision Medicine tool capable of predicting 5-year risk, that can also guide personalized prevention interventions and monitor changes in risk over time. It was developed using an application of AI, machine learning, in the Framingham Heart Study to mine integrated genetic-epigenetic biosignatures that capture the complex interplay between our genome and the environment in conferring risk for CHD. The training and test sets consisted of 1180 (19/695 females and 23/485 males developed symptomatic CHD within 5-years) and 524 (8/293 females and 12/231 males developed symptomatic CHD within 5-years) individuals, respectively, of Northern European ancestry. Non-linear data mining and modeling techniques were employed on the training set to identify prediction signatures from genome-wide SNP and DNA methylation (DNAm) data. We identified 14 DNAm and 10 SNPs from the training set (training bootstrap average sensitivity and specificity of 0.61 and 0.71, respectively) that predicted the 5-year risk in the test set with a sensitivity and specificity of 0.60 and 0.69, respectively. Performance was compared to that of the Framingham Risk Score (FRS) and the ASCVD Risk Estimator. The sensitivity and specificity in the test set were 0.05 and 0.99 for FRS, and 0.38 and 0.85 for ASCVD. Even with a small number of incident cases, our tool performed with superior sensitivity, which is vital because, while a false positive would result in additional testing, a false negative can be detrimental. Unlike genetics, because DNAm is dynamic, it can be mapped to actionable risk factors to guide personalized interventions and over time, re-assess risk and continuously monitor heart health. We demonstrate translational feasibility of this tool via next-gen digital PCR assays. Additional efforts are ongoing to optimize, validate and extend our tool to further improve performance in larger, more ethnically diverse cohorts.

5‐Aminosalicylic Acid Therapy and the Risk of Colorectal Cancer Among Patients with Inflammatory Bowel Disease

Practical Importance of Genetic Research Results when Developing an Insurance Product for Personal Insurance: International Experience

Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges

Genetic risk prediction in complex disease

A Non-Parametric Method for Building Predictive Genetic Tests on High-Dimensional Data

Advantageous Effects of Regulatory Adverse Selection in the Life Insurance Market

"Uninsurable because of a genetic test": a qualitative study of consumer views about the use of genetic test results in Australian life insurance

Improving the Accuracy and Transparency of Underwriting with AI to Transform the Life Insurance Industry

Gene-Based Association Analysis for Censored Traits Via Fixed Effect Functional Regressions

The personal and clinical utility of polygenic risk scores

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Genomic Prediction of Complex Disease Risk

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Polygenic risk scores: from research tools to clinical instruments

Abstract 16592: A Next-Generation Artificial Intelligence-Based Integrated Genetic-Epigenetic Prediction of 5-Year Risk for Coronary Heart Disease

Integrated Health-Related Phenotype by Polygenic Risk Scores Stratifies Risk Population for All-Cause Mortality: A Cohort Study Based on UK Biobank

Effective Genetic Risk Prediction Using Mixed Models

A comprehensive investigation of statistical and machine learning approaches for predicting complex human diseases on genomic variants

Genetic Risk Score: Principle, Methods and Application

Polygenic hazard score models for the prediction of Alzheimer’s free survival using the lasso for Cox’s proportional hazards model